Our results suggest that the expression of MK3 was positively correlated to the majority of immunoinhibitors (Figures 7A, B), pro-tumor chemokines (Figures 7C, D), and chemokine receptors (Figures 7E, F) in both GBM and LGG patients. The gene discussed is MAPKAPK3; the disease is glioblastoma.